Hepatitis B immunoglobulin injection in late pregnancy for HBeAg- negative carrier mothers to interrupt hepatitis B virus intrauterine infection: a meta analysis

FEI Man-dong,LI Hui,WANG Qiong,HUANG Yuan,LI Chang-chang,HUANG Rong,LI Jia-yuan
2013-01-01
Abstract:OBJECTIVE To evaluate the efficiency of using hepatitis B immunoglobulin (HBIG) during late pregnancy to prevent hepatitis B virus intrauterine infection for HBeAg-negative carrier mothers. METHODS According to the criteria for inclusion, literatures about HBIG in interruption of mother-to-infant transmission of HBV from 2000 to now were searched extensively and then assessed with JADAD’s standard. We used Meta-analysis software, Revman 5.1, to test the heterogeneity of the researches, and calculate the pooled ratio difference (RD) with 95%CI. Sensitivities of the results were analyzed, and publication bias was evaluated by Egger’s test. RESULTS A total of 1826 newborns of asymptomatic HBsAg-positive but HBeAg-negative carrier mothers from 12 qualified RCTs were included. Compared with control group, newborns in HBIG group had a lower intrauterine infection rate (RD = -0.18, 95%CI: -0.11- -0.04, P﹤0.0001). In subgroups, stratified by different diagnosis standard of intrauterine infection, Standard 1 (HBsAg-positive in peripheral blood of neonate before injection of HBV vaccine and Hepatitis B immunoglobulin) and Standard 2 (HBsAg-positive in peripheral blood lasts for positive for more than three months from born), we found that there were obviously differences of intrauterine infection rate between intervention group and control group in any subgroups ( Merger effect value, RD ( 95% CI) ; -0.10 ( -0.15 - -0.04) for Standard 1and -0.05 (-0.09- -0.02) for Standard 2). CONCLUSION Multiple injection of HBIG in HBeAg-negative HBV carrier mothers in late pregnancy can prevent HBV intrauterine transmission effectively and safely.
What problem does this paper attempt to address?